Clinical trial
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab…
NCT04139317 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT04139317 |
|---|---|
| Title | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% |
| Official title | A Randomized, Open Label, Multicenter Phase II Study Evaluating the Efficacy and Safety of Capmatinib (INC280) Plus Pembrolizumab Versus Pembrolizumab Alone as First Line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer With PD-L1≥ 50% |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer (NSCLC) |
| Intervention type | Biological, Drug |
| Interventions | Capmatinib, Pembrolizumab |
| Enrollment | 76 |
| Start date | Jan 22, 2020 |
| Primary completion | Jan 14, 2022 |
| Completion | Feb 7, 2023 |
| First posted | Oct 25, 2019 |
| Last update posted | Oct 9, 2024 |
| Countries | Australia, Belgium, Canada, Czechia, France, Germany, Greece, Hong Kong, India, Italy, Japan, Malaysia and 4 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: